Health ❯ Healthcare ❯ Pharmacology
Nivolumab Pembrolizumab OX40 Inhibitors Tislelizumab Chemo-immunotherapy PD-L1 Inhibitors Bispecific T-cell Engagers Cemiplimab Avelumab Nivolumab and Ipilimumab Durvalumab
The move reflects phase 3 C-POST evidence showing a substantial disease-free survival benefit in resected high-risk CSCC.
